Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
Launched by STANFORD UNIVERSITY · Feb 7, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called Dipyridamole to see if it can help kidney transplant patients maintain healthy phosphate levels in their blood. Phosphate is an important mineral, and low levels, known as hypophosphatemia, can lead to health issues. The goal is to find out if Dipyridamole can improve these phosphate levels and reduce the need for extra phosphate supplements.
To take part in this trial, participants need to be adults who have received a kidney transplant and do not have any known reasons that would prevent them from using Dipyridamole. However, individuals who experienced delays in their kidney function after the transplant or who are taking certain blood-thinning medications won't be eligible. If you join the trial, you'll be closely monitored to see how well Dipyridamole works for you. This study is not yet recruiting participants, but it's an important step toward improving care for kidney transplant recipients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult kidney transplant patients.
- • No known contraindications to Dipyridamole
- Exclusion Criteria:
- • Contraindications to Dipyridamole.
- • Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
- • Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
Stephan Busque, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported